- Home
- HOWL vs ABVC Comparison
HOWL vs ABVC Comparison
Compare HOWL & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- ABVC
- Stock Information
- Founded
- HOWL 2017
- ABVC 2015
- Country
- HOWL United States
- ABVC United States
- Employees
- HOWL N/A
- ABVC N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- ABVC Health Care
- Exchange
- HOWL Nasdaq
- ABVC Nasdaq
- Market Cap
- HOWL 64.5M
- ABVC 68.7M
- IPO Year
- HOWL 2021
- ABVC N/A
- Fundamental
- Price
- HOWL $0.99
- ABVC $2.71
- Analyst Decision
- HOWL Strong Buy
- ABVC
- Analyst Count
- HOWL 5
- ABVC 0
- Target Price
- HOWL $7.00
- ABVC N/A
- AVG Volume (30 Days)
- HOWL 670.5K
- ABVC 61.4K
- Earning Date
- HOWL 11-04-2025
- ABVC 11-03-2025
- Dividend Yield
- HOWL N/A
- ABVC N/A
- EPS Growth
- HOWL N/A
- ABVC N/A
- EPS
- HOWL N/A
- ABVC N/A
- Revenue
- HOWL N/A
- ABVC $797,916.00
- Revenue This Year
- HOWL N/A
- ABVC $735.18
- Revenue Next Year
- HOWL N/A
- ABVC N/A
- P/E Ratio
- HOWL N/A
- ABVC N/A
- Revenue Growth
- HOWL N/A
- ABVC 56.52
- 52 Week Low
- HOWL $0.60
- ABVC $0.40
- 52 Week High
- HOWL $2.38
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- HOWL 37.92
- ABVC 45.16
- Support Level
- HOWL $0.80
- ABVC $2.45
- Resistance Level
- HOWL $1.03
- ABVC $3.06
- Average True Range (ATR)
- HOWL 0.10
- ABVC 0.18
- MACD
- HOWL 0.01
- ABVC -0.02
- Stochastic Oscillator
- HOWL 43.93
- ABVC 40.98
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.